<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0121-8123</journal-id>
<journal-title><![CDATA[Revista Colombiana de Reumatología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Colomb.Reumatol.]]></abbrev-journal-title>
<issn>0121-8123</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Reumatología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0121-81232023000200102</article-id>
<article-id pub-id-type="doi">10.1016/j.rcreu.2021.08.001</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Caracterización del perfil lipídico en pacientes con síndrome de Sjögren primario]]></article-title>
<article-title xml:lang="en"><![CDATA[Characterization of the lipid profile in patients with primary Sjögren's syndrome]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quevedo Mayorga]]></surname>
<given-names><![CDATA[Pedro Arbey]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mora Méndez]]></surname>
<given-names><![CDATA[Javier Mauricio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cuervo Martínez]]></surname>
<given-names><![CDATA[Jessica Andrea]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Amador Suárez]]></surname>
<given-names><![CDATA[Henry Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario Clínica San Rafael Departamento de Medicina Interna Servicio de Reumatología]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<volume>30</volume>
<numero>2</numero>
<fpage>102</fpage>
<lpage>109</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0121-81232023000200102&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0121-81232023000200102&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0121-81232023000200102&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  La dislipidemia es la alteración metabólica más prevalente en el síndrome de Sjögren primario (SSP), se sugiere una asociación entre niveles bajos de colesterol de alta densidad (HDL) y la actividad de la enfermedad.  Objetivos:  El propósito de este estudio es describir las características del perfil lipídico y explorar la correlación entre sus componentes y la actividad del SSP.  Materiales y métodos:  Estudio descriptivo de corte trasversal, se revisaron las historias clí nicas de pacientes mayores de 18 años que asistieron al Hospital Universitario Clínica San Rafael, con criterios clasificatorios para SSP durante el periodo de enero del 2015 a diciembre del 2019. Para el análisis estadístico se utilizó el software RStudio versión 4.0.2. Se efectuó un análisis descriptivo de las variables clínico-demográficas y serológicas para evaluar la correlación entre ellas.  Resultados:  Se revisaron en total 250 historias clínicas, de las cuales, 35 cumplían con los criterios de inclusión. La edad promedio fue de 53,4 años; el 88,3% de la población fueron mujeres. La mediana del tiempo de enfermedad fue de 42 meses. Las medias de colesterol total, HDL, colesterol de baja densidad (LDL) y triglicéridos fueron de 191 mg/dL, 42,6 mg/dL, 118,9 mg/dL y 157 mg/dL, respectivamente. Se encontró un coeficiente de correlación de Pearson entre el índice de actividad ESSDAI y el colesterol HDL de -0,43 (IC 95% -0,67-0,12), valor p = 0,008. Se realizó un modelo lineal entre el índice de actividad ESSDAI total y el colesterol HDL, y como resultado se halló un coeficiente estimado de -0,17. La curva ROC, con un punto de segregación de colesterol HDL de 43,5 mg/dL, mostró un área bajo la curva (AUC) de 0,603 (IC 95% 0,40-0,80). Al excluir los pacientes con índice de masa corporal (IMC) alto, el AUC mejoró, con un punto de segregación de 38 mg/dL.  Conclusiones:  Los pacientes con niveles bajos de colesterol HDL mostraron mayores índices de actividad de la enfermedad, con un punto de corte menor a 43 mg/dL, siendo más marcado en pacientes con IMC normal.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Dyslipidaemia is the most prevalent metabolic disorder in primary Sjögren s syndrome (PSS) and an association between low HDL cholesterol levels and disease activity has been suggested.  Objectives:  The purpose of this study is to describe the characteristics of the lipid profile in patients with PSS and explore the correlation between the components of the lipid profile and the activity of the disease.  Materials and methods:  A descriptive cross-sectional study. We reviewed the medical records of patients over 18 years of age with criteria for PSS who attended the Hospital Universitario Clínica San Rafael during the period between January 2015 to December 2019. We used R-studio software version 4.0.2 for statistical analysis. A descriptive analysis of the clinical-demographic and serological variables was carried out to evaluate the correlation between them.  Results: A total of 250 medical records were reviewed, of which 35 met the inclusion criteria. The average age was 53.4 years and 88.3% were women. The median duration of disease was 42 months. The mean values for total cholesterol, HDL, LDL and triglycerides were 191 mg/dL, 42.6 mg/dL, 118.9 mg/dL and 157 mg/dL respectively. A Pearson correlation coefficient of -.43 (95% CI -.67 to -.12) p-value = .008 was found between the ESSDAI activity index and HDL cholesterol. A linear model was performed between the total ESSDAI activity index and HDL cholesterol, finding an estimated coefficient of -.17. A ROC curve was performed with an HDL cholesterol segregation point of 43.5 mg/dL with an area under the curve of .603 (95% CI .40-.80). By excluding patients with high BMI, the area under the curve improved with a segregation point of 38 mg/dL.  Conclusions:  Patients with low levels of HDL cholesterol showed higher rates of disease activity, with a cut-off point lower than 43 mg/dL being more marked in patients with normal body mass index.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Síndrome de Sjögren]]></kwd>
<kwd lng="es"><![CDATA[Colesterol total]]></kwd>
<kwd lng="es"><![CDATA[Colesterol de baja densidad]]></kwd>
<kwd lng="es"><![CDATA[Colesterol de alta densidad]]></kwd>
<kwd lng="es"><![CDATA[Autoanticuerpos]]></kwd>
<kwd lng="en"><![CDATA[Sjögren's syndrome]]></kwd>
<kwd lng="en"><![CDATA[Total cholesterol]]></kwd>
<kwd lng="en"><![CDATA[Low-density cholesterol]]></kwd>
<kwd lng="en"><![CDATA[High-density cholesterol]]></kwd>
<kwd lng="en"><![CDATA[Autoantibodies]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Both]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dalm]]></surname>
<given-names><![CDATA[VASH]]></given-names>
</name>
<name>
<surname><![CDATA[van Hagen]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[van Daele]]></surname>
<given-names><![CDATA[PLA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reviewing primary Sjögren's syndrome: beyond the dryness - From pathophysiology to diagnosis and treatment]]></article-title>
<source><![CDATA[Int J Med Sci]]></source>
<year>2017</year>
<numero>14</numero>
<issue>14</issue>
<page-range>191-200</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ienopoli]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Carsons]]></surname>
<given-names><![CDATA[SE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Extraglandular manifestations of primary Sjögren's syndrome]]></article-title>
<source><![CDATA[Oral Maxillofac Surg Clin North Am]]></source>
<year>2014</year>
<numero>26</numero>
<issue>26</issue>
<page-range>91-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Durigan]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Secco]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Duarte V.Troitiiio]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Catalan Pellet]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mamani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Manifestaciones cutáneas extraglandulares en pacientes con síndrome de Sjögren primario]]></article-title>
<source><![CDATA[Rev Colomb Reumatol]]></source>
<year>2018</year>
<numero>25</numero>
<issue>25</issue>
<page-range>79-84</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramos-Casals]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brito-Zerón]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sisó]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vargas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ros]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bove]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High prevalence of serum metabolic alterations in primary Sjögren's syndrome: influence on clinical and immunological expression]]></article-title>
<source><![CDATA[J Rheumatol]]></source>
<year>2007</year>
<numero>34</numero>
<issue>34</issue>
<page-range>754-61</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[HC.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comorbidities in patients with primary Sjögren's syndrome: a registry-based case-control study]]></article-title>
<source><![CDATA[J Rheumatol.]]></source>
<year>2010</year>
<numero>37</numero>
<issue>37</issue>
<page-range>1188-94</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lodde]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Sankar]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Kok]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Leakan]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Tak]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
<name>
<surname><![CDATA[Pillemer]]></surname>
<given-names><![CDATA[SR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum lipid levels in Sjögren's syndrome]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2006</year>
<numero>45</numero>
<issue>45</issue>
<page-range>481-4</page-range><publisher-loc><![CDATA[Oxford ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vaudo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bocci]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
<name>
<surname><![CDATA[Shoenfeld]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Schillaci]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Del Papa]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Precocious intima-media thickening in patients with primary Sjögren's syndrome]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>2005</year>
<numero>52</numero>
<issue>52</issue>
<page-range>3890-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramos-Casals]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brito-Zerón]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bombardieri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bootsma]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[De Vita]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dorner]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2020</year>
<numero>79</numero>
<issue>79</issue>
<page-range>3-18</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Posso-Osorio]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Méndez-Rayo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Soto]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Nieto-Aristizábal]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Caíías]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Tobón]]></surname>
<given-names><![CDATA[GJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinimetría en el síndrome de Sjögren]]></article-title>
<source><![CDATA[Rev Colomb Reumatol]]></source>
<year>2019</year>
<numero>26</numero>
<issue>26</issue>
<page-range>262-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mariette]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Criswell]]></surname>
<given-names><![CDATA[LA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary Sjögren's syndrome]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2018</year>
<numero>378</numero>
<issue>378</issue>
<page-range>931-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Catapano]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Pirillo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bonacina]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Norata]]></surname>
<given-names><![CDATA[GD.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HDL in innate and adaptive immunity]]></article-title>
<source><![CDATA[Cardiovasc Res.]]></source>
<year>2014</year>
<numero>103</numero>
<issue>103</issue>
<page-range>372-83</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diez Morrondo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lema Gontad]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez Rivas]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Atanes Sandoval]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[De Toro Santos]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pinto Tasende]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspectos actuales del síndrome de Sjögren: etiopatogenia, manifestaciones clínicas, diagnóstico y tratamiento.]]></article-title>
<source><![CDATA[Semin Fund Esp Reumatol]]></source>
<year>2010</year>
<numero>11</numero>
<issue>11</issue>
<page-range>70-6</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gravani]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Papadaki]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Antypa]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Nezos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Masselou]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ioakeimidis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Subclinical atherosclerosis and impaired bone health in patients with primary Sjögren's syndrome: prevalence, clinical and laboratory associations]]></article-title>
<source><![CDATA[Arthritis Res Ther]]></source>
<year>2015</year>
<numero>17</numero>
<issue>17</issue>
<page-range>9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Servioli]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Maciel]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Nannini]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Crowson]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Matteson]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Cornec]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of smoking and obesity on the risk of developing primary Sjögren syndrome: a population-based cohort study]]></article-title>
<source><![CDATA[J Rheumatol]]></source>
<year>2019</year>
<numero>46</numero>
<issue>46</issue>
<page-range>727-30</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Madsen]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Varbo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nordestgaard]]></surname>
<given-names><![CDATA[BG.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low HDL cholesterol and high risk of autoimmune disease: two population-based cohort studies including 117341 individuals]]></article-title>
<source><![CDATA[Clin Chem]]></source>
<year>2019</year>
<numero>65</numero>
<issue>65</issue>
<page-range>644-52</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bartoloni]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Alunno]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Valentini]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Valentini]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Leone]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Cafaro]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The prevalence and relevance of traditional cardiovascular risk factors in primary Sjögren's syndrome.]]></article-title>
<source><![CDATA[Clin Exp Rheumatol]]></source>
<year>2018</year>
<numero>36</numero>
<issue>36</issue>
<page-range>113-20</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Augusto]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Bonfa]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[RMR]]></given-names>
</name>
<name>
<surname><![CDATA[Bueno]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Leon]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<name>
<surname><![CDATA[Viana]]></surname>
<given-names><![CDATA[VST]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolic syndrome in Sjögren's syndrome patients: a relevant concern for clinical monitoring.]]></article-title>
<source><![CDATA[Clin Rheumatol.]]></source>
<year>2016</year>
<numero>35</numero>
<issue>35</issue>
<page-range>639-47</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Fialho]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Morato]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Castro]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zimmermann]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ribeiro]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is there a link between inflammation and abnormal lipoprotein profile in Sjögren's syndrome?]]></article-title>
<source><![CDATA[Joint Bone Spine.]]></source>
<year>2010</year>
<numero>77</numero>
<issue>77</issue>
<page-range>229-31</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
